Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02912754

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

A Phase I/II Trial of Ruxolitinib in Chronic Lymphocytic Leukemia Patients at Risk for Progression on Ibrutinib

Sponsor: Novartis

Conditions Leukemia, Lymphocytic, Chronic, B-Cell

Updated 8 times since 2017 Last updated: Mar 8, 2017 Started: Mar 31, 2017 Primary completion: Dec 31, 2018 Completion: Aug 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Leukemia, Lymphocytic, Chronic, B-Cell and is currently ongoing. Novartis leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Sep 2019 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Sep 2019 [monthly]

Not Yet Recruiting PHASE1_PHASE2

▶ Show 3 earlier versions

May 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Feb 2017 — May 2017 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Sunnybrook Health Sciences Centre

Data source: Sunnybrook Health Sciences Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada